Will The Decline in Legacy Drugs Pull Down BMY's Top Line?

Key Takeaways BMY's legacy portfolio revenues fell 20% in Q1, hit by generics and Medicare Part D redesign. Revlimid, Pomalyst, Sprycel and Abraxane all saw double-digit sales declines from generic competition. Eliquis dropped 4%, but BMY expects recovery in H2 2025 as Medicare coverage gap is eliminated.Bristol Myers’ (BMY) legacy portfolio comprises Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane.Revenues for the Legacy Portfolio plunged 20% in the first quarter to $5.64 billion due to the continued g ...